Akcea Therapeutics, Inc. AKCA Balance Sheet

Akcea therapeutics, inc. (AKCA)

Balance Sheet / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Dec'16
ASSETS
Current assets:
Cash and cash equivalents
163,320	306,866	129,329	150,234	201,027	86,454	116,206	216,840	69,907	58,367	110,366	75,445	7,857
Short-term investments
257,982	156,806	123,362	145,374	120,765	166,155	204,109	165,011	175,028	201,763	175,765	43,223	0
Accounts receivable
10,673	10,496	10,653	9,193	10,269	4,597	636	3,295	0	5,413	-	-	0
Receivable from Ionis Pharmaceuticals, Inc.
2,432	3,231	647	7,911	7,206	-	-	-	-	-	-	-	-
Inventories
13,723	8,817	8,641	8,286	-	85	-	-	-	-	-	-	-
Contracts receivable
-	-	-	-	-	-	-	-	-	-	500	-	-
Other current assets
10,813	10,689	5,809	6,713	11,618	9,944	8,397	3,575	5,628	1,302	1,249	3,939	1,209
Total current assets
458,943	496,905	278,441	327,711	350,885	267,235	329,348	388,721	250,563	266,845	287,880	122,607	9,066
Property, plant and equipment, net
5,437	5,261	5,277	5,443	5,336	5,696	5,757	1,523	50	77	104	114	177
Operating lease right-of-use assets
10,868	11,094	11,300	11,534	11,602	-	-	-	-	-	-	-	-
Intangible assets, net
81,589	83,051	84,529	86,006	87,468	88,914	40,969	1,714	1,191	1,221	1,251	1,281	1,341
Deposits and other assets
3,084	2,939	3,620	3,426	3,426	3,416	3,054	3,047	661	661	114	102	100
Total assets
559,921	599,250	383,167	434,120	458,717	365,261	379,128	395,005	252,465	268,804	289,349	124,104	10,684
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
10,372	10,216	5,711	7,936	6,153	12,068	3,071	2,706	2,578	2,381	2,012	143	476
Payable to Ionis Pharmaceuticals, Inc.
-	-	-	-	-	18,901	23,888	27,137	27,737	14,365	9,501	11,244	24,355
Accrued compensation
6,996	12,793	9,382	7,521	6,300	8,583	8,848	4,548	3,773	4,083	2,307	1,252	2,505
Accrued liabilities
14,131	14,191	15,211	17,569	17,255	14,787	21,151	25,969	13,413	7,570	3,452	2,213	1,041
Deferred revenue
832	2,165	10,840	15,830	21,539	25,354	32,347	35,713	48,866	58,192	54,043	54,155	0
Other current liabilities
4,001	2,633	1,977	1,713	1,863	968	1,295	1,138	1,929	1,875	2,142	40	33
Total current liabilities
36,332	41,998	43,121	50,569	53,110	80,661	90,600	97,211	98,296	88,466	73,457	69,047	28,410
Long-term portion of lease liabilities
13,898	14,248	14,558	14,909	15,018	4,442	-	-	-	-	-	-	-
Long-term portion of deferred rent
-	-	-	-	-	-	4,653	1,551	10	12	14	18	21
Long-term portion of deferred revenue
-	-	-	-	1,725	3,434	2,464	5,839	7,859	12,501	18,035	30,515	0
Line of credit with Ionis Pharmaceuticals, Inc.
-	-	-	-	-	-	-	-	-	-	-	107,507	-
Total liabilities
50,230	56,246	57,679	65,478	69,853	88,537	97,717	104,601	106,165	100,979	91,506	207,087	28,431
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; no and 28,884,540 shares authorized, no and 28,884,540 shares issued and outstanding at December 31, 2017 and 2016, respectively; aggregate liquidation value of $0 and $610,304 as of December 31, 2017 and 2016, respectively
-	-	-	-	-	-	-	-	-	-	0	100,000	100,000
Common stock, $0.001 par value; 125,000,000 shares authorized at March 31, 2020 and December 31, 2019; 101,348,633 and 100,993,173 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively.
101	101	94	93	93	89	87	86	67	67	67	0	0
Additional paid-in capital
1,033,319	1,024,168	889,133	900,837	883,653	799,001	733,098	678,509	472,549	464,430	459,050	64,059	56,936
Accumulated other comprehensive income
391	5	-63	-110	-27	-324	-289	-297	-468	-451	-222	-84	-21
Accumulated deficit
-524,120	-481,270	-563,676	-532,178	-494,855	-522,042	-451,485	-387,894	-325,848	-296,221	-261,052	-246,958	-174,662
Total stockholders’ equity
509,691	543,004	325,488	368,642	388,864	276,724	281,411	290,404	146,300	167,825	197,843	-82,983	-17,747
Total liabilities and stockholders’ equity
559,921	599,250	383,167	434,120	458,717	365,261	379,128	395,005	252,465	268,804	289,349	124,104	10,684